Cancer Chemotherapy and Pharmacology

, Volume 64, Issue 3, pp 565–573

Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation

  • Koichi Azuma
  • Tetsuro Sasada
  • Akihiko Kawahara
  • Satoshi Hattori
  • Takashi Kinoshita
  • Sinzo Takamori
  • Masao Ichiki
  • Youhei Imamura
  • Jiro Ikeda
  • Masayoshi Kage
  • Michihiko Kuwano
  • Hisamichi Aizawa
Original Article

DOI: 10.1007/s00280-008-0907-3

Cite this article as:
Azuma, K., Sasada, T., Kawahara, A. et al. Cancer Chemother Pharmacol (2009) 64: 565. doi:10.1007/s00280-008-0907-3

Abstract

Introduction

The expression of excision repair cross-complementation group 1 (ERCC1) is reported to be correlated with resistance to platinum-based drugs. Class III β-tubulin is reported to be correlated with resistance to taxanes.

Methods

In the present study, we evaluated whether ERCC1 and class III β-tubulin expression could be used to predict progression-free and/or overall survival in 34 patients with locally advanced non-small cell lung cancer (NSCLC) receiving concurrent chemoradiation therapy with cisplatin and docetaxel, and immunohistochemistry was used to examine the expression of these two proteins in tumor samples obtained from the patients.

Results

Immunostaining for ERCC1 and class III β-tubulin was positive in 16 and 12 patients, respectively. A significant correlation was observed between ERCC1 expression and response to chemotherapy (P = 0.012), and between class III β-tubulin expression and histology (P = 0.029). Patients negative for ERCC1 had a significantly longer median progression-free (62.5 vs. 36 weeks, P = 0.009), but not overall (171 vs. 50.5 weeks, P = 0.208), survival than those positive for ERCC1. Expression of class III β-tubulin was not correlated with progression-free or overall survival (P = 0.563 and P = 0.265, respectively). Multivariate analysis adjusting for possible confounding factors showed that negative ERCC1 expression (hazard ratio = 3.972, P = 0.009) was a significantly favorable factor for progression-free survival.

Conclusions

This retrospective study indicates that immunostaining for ERCC1 may be useful for predicting survival in NSCLC patients receiving concurrent chemoradiotherapy with cisplatin and docetaxel, and can provide information critical for planning personalized chemotherapy.

Keywords

ERCC1Class III β-tubulinNSCLCChemoradiation

Abbreviations

NSCLC

Non-small cell lung cancer

ERCC1

Excision repair cross-complementation group 1

p-stage

Pathological stage

RECIST

Response evaluation criteria in solid tumors

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Koichi Azuma
    • 1
    • 4
  • Tetsuro Sasada
    • 6
  • Akihiko Kawahara
    • 2
    • 4
  • Satoshi Hattori
    • 5
  • Takashi Kinoshita
    • 1
  • Sinzo Takamori
    • 3
  • Masao Ichiki
    • 1
    • 7
  • Youhei Imamura
    • 1
  • Jiro Ikeda
    • 1
  • Masayoshi Kage
    • 2
    • 4
  • Michihiko Kuwano
    • 4
  • Hisamichi Aizawa
    • 1
  1. 1.Division of Respirology, Neurology, and Rheumatology, Department of Internal MedicineKurume University School of MedicineKurumeJapan
  2. 2.Department of PathologyKurume University School of MedicineKurumeJapan
  3. 3.Department of SurgeryKurume University School of MedicineKurumeJapan
  4. 4.Research Center for Innovative Cancer TherapyKurume University School of MedicineKurumeJapan
  5. 5.Biostatistics CenterKurume UniversityKurumeJapan
  6. 6.Department of Surgery, Kitano HospitalTazuke-Kofukai Medical Research InstituteOsakaJapan
  7. 7.Department of Respiratory MedicineNational Hospital Organization, Kyushu Medical CenterChuo-kuJapan